phase I clinical study
BerGenBio, Tempus Partner for Bemcentinib Trial in STK11-Mutant NSCLC
Tempus will provide clinical and molecular data to function as a synthetic control arm for an ongoing single-arm study of bemcentinib plus chemo and immunotherapy.
Researchers hope their study will show that tests for gene variants and DNA methylation can predict which lower-risk patients may be cured without a stem cell transplant.
Tempus, Actuate Therapeutics Ink Collaboration to Discover Biomarkers of Response for Elraglusib
Tempus will provide its clinical xF+ liquid biopsy and research-use-only DNA methylation tests to the ongoing Phase I/II trial of Actuate's GSK-3β inhibitor elraglusib.
The consumer genetics firm will soon be able to team with other drug companies as it mines its genotypic database for new disease pathways.
Caris Life Sciences, Essa Pharma Ink Liquid Biopsy Partnership for Prostate Cancer Trial
Essa will use Caris' blood-based sequencing tests to assess the genetic profiles of mCRPC patients enrolled in a Phase I trial of the firm's investigational agent.